An incredible discovery that could revolutionise cancer treatment was made in March 2024.

The therapeutic experiment, which was used to treat glioblastoma, a deadly kind of brain cancer, showed “dramatic responses within days” for the trial participants.

A novel method to CAR-T therapy, a sophisticated and individualised treatment that triggers your immune system to attack the cancer cells,

is being used by researchers and surgeons from the Mass General Brigham healthcare system.

Utilising the patient’s own immune system, CAR-T therapy is typically used to treat leukaemia.

Before being returned to the patient and used to treat their ailment, a patient’s blood is usually extracted and sent to a laboratory to be “trained” to combat the cancer cells.

Source: Pexels
In this instance, the researchers and surgeons used an existing CAR-T therapy variation in conjunction with antibodies to treat three patients with recurrent glioblastoma, and the outcomes were astounding.

Within two days of treatment, one patient’s tumour size shrank by 18.5%, according to a study published in The New England Journal of Medicine. The tumour shrank by a remarkable 60.7% on day 69. The Mass General Brigham said that another patient’s “tumour regressed rapidly.”

An MRI performed five days after the third patient’s therapy revealed that a single infusion had caused “near-complete tumour regression.”

“The CAR-T platform has revolutionized how we think about treating patients with cancer, but solid tumors like glioblastoma have remained challenging to treat because not all cancer cells are exactly alike and cells within the tumor vary,” said Bryan Choi, MD, PhD, neurosurgeon and associate director of the Center for Brain Tumor Immunology and Immunotherapy, Cellular Immunotherapy Program, Mass General Cancer Center and Department of Neurosurgery.

He continued, “Our approach combines two forms of therapy, allowing us to treat glioblastoma in a broader, potentially more effective way.”

Studies like this one “show the promise of cell therapy for treating incurable conditions,” according to Mass General Brigham, offering sufferers a great deal of hope.

Although CAR-T treatments are typically used to treat blood cancers, this study demonstrates that they may also be utilised to treat solid tumours.

This is encouraging for those who suffer from these illnesses,

but it is important to remember that this was only a small trial involving three individuals, and further research is required before the treatment is made more generally available for solid tumours.

Study co-author Elizabeth Gerstner, MD, a neuro-oncologist in the Department of Neurology at Massachusetts General Hospital, said,

“We report a dramatic and rapid response in these three patients. Our work to date shows signs that we are making progress, but there is more to do.”

Marcela Maus, MD, PhD, director of the Cellular Immunotherapy Program agreed, and said,

“These results are exciting, but they are also just the beginning – they tell us that we are on the right track in pursuing a therapy that has the potential to change the outlook for this intractable disease. We haven’t cured patients yet, but that is our audacious goal.”